Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Zymeworks BC Inc shares valued at $138,762 were sold by Hollywood Mark on Jan 12 ’26. At $22.67 per share, Hollywood Mark sold 6,120 shares. The insider’s holdings dropped to 132,913 shares worth approximately $3.18 million following the completion of this transaction.
Also, Smith Jeffrey T L sold 9,310 shares, netting a total of over 211,090 in proceeds. Following the sale of shares at $22.67 each, the insider now holds 26,708 shares.
Before that, Moore Paul Andrew had sold 9,560 shares from its account. In a trade valued at $216,759, the Chief Scientific Officer traded Zymeworks BC Inc shares for $22.67 each. Upon closing the transaction, the insider’s holdings decreased to 9,560 shares, worth approximately $1.16 million.
As published in a research note from Wells Fargo on December 12, 2025, Zymeworks BC Inc [ZYME] has been rated up from an Equal weight to an Overweight and the price target has been revised to $33. Analysts at Citizens JMP started covering the stock with ‘”a Mkt outperform”‘ outlook in a report released in early December. Earlier on October 14, 2025, H.C. Wainwright upgraded its rating. Their new recommendation was “a Buy” for ZYME stock which previously was a “a Neutral”.
Analyzing ZYME Stock Performance
On last trading session, Zymeworks BC Inc [NASDAQ: ZYME] rose 1.18% to $23.95. The stock’s lowest price that day was $23.475, but it reached a high of $24.17 in the same session. During the last five days, there has been a surge of approximately 0.13%. Over the course of the year, Zymeworks BC Inc shares have jumped approximately 72.55%.
Is Zymeworks BC Inc subject to short interest?
Stocks of Zymeworks BC Inc saw a sharp steep in short interest on 2025-12-31 dropping by -2.01 million shares to 3.6 million. Data from Yahoo Finance shows that the short interest on 2025-11-28 was 5.61 million shares. A decline of -55.65% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 5.68 of the overall float, the days-to-cover ratio (short ratio) decline to 5.68.
Which companies own the most shares of Zymeworks BC Inc (ZYME)?
In terms of Zymeworks BC Inc share price expectations, FactSet research, analysts set an average price target of 35 in the next 12 months, up nearly 47.87% from the previous closing price of $23.67. Analysts anticipate Zymeworks BC Inc stock to reach 40 by 2026, with the lowest price target being 26. In spite of this, 4 analysts ranked Zymeworks BC Inc stock as Buy at the end of 2026. On October 10, 2025, B. Riley Securities assigned a price target of “a Buy” to the stock and initiated coverage with a $30.
